• Skip to main content
  • Skip to primary sidebar
Transfusion News
  • About Us
  • Topics
    • Adverse Events (non-infectious)
    • Blood Donation
    • Cell Therapy
    • Coagulation & Plasma Transfusion
    • Platelet Transfusion
    • Policy and Guidelines
    • Quality Control and Regulatory
    • RBC Transfusion
    • Serology/Genotyping
    • Special Transfusion Situations
    • Transfusion Transmitted Infections
  • Continuing Education
  • Archives
  • Podcasts
  • Question of the Day
  • Search
  • Subscribe to Email Alerts
  • Follow us on
  • Search
  • Subscribe to Email Alerts

Anti-CD47 Interference with Serological Testing

February 6, 2019

Immunotherapy, the use of humanized monoclonal antibodies, is a promising therapy that works in conjunction with the patient’s own immune system to target and mark cancerous cells for destruction. Anti-CD38, or daratumumab, targets the CD38 protein expressed on certain types of cancer cells.  Anti-CD38, unfortunately, also interferes with serological testing.  CD38, luckily, can be denatured with dithiothreitol (DTT) allowing for subsequent alloantibody testing. A new monoclonal IgG4 antibody, anti-CD47 (Hu5F9-G4) is currently in clinical trials for treatment of hematologic and solid malignancies.  CD47 is a glycoprotein expressed on all cells including RBCs and platelets, which usually signals to prevent phagocytosis.  Anti-CD47 blocks this signal targeting cells for destruction. Researchers recently investigated the interference of this new drug in pre-transfusion serological testing using samples from four patients taking anti-CD47.  Anti-CD47 interfered with all RBC and platelet serological tests performed including ABO reverse typing.  In addition, CD47 could not be denatured with DDT or other common denaturing agents.  The best mitigation strategy for blood bankers includes requesting drug history for patients requiring transfusions, performing multiple RBC alloadsorptions, and using monoclonal Gamma-clone IgG in indirect antigen testing (which does not detect IgG4s like anti-CD47).  Practical and cost-effective approaches for serological testing for patients taking anti-CD47 need further investigation.

Learn More:

Read the article in TRANSFUSION (free access)

Listen to the Blood Bank Guy Essentials Podcast: Anti-CD47 Testing Interference with Connie Westhoff  

Answer the Transfusion Medicine Question of the Day. Not already on our e-mail list?  Click “Join” on the “Transfusion Medicine Questions” page to have the “Question of the Day” emailed to you every Monday, Wednesday and Friday.

Reference:

Velliquette R, Aeschlimann J, Kirkegaard J, Shakarian G, Lomas-Francis C, and C. Westhoff. Monoclonal anti-CD47 interference in red cell and platelet testing.  Transfusion 2019 

 

Filed Under

  • News
  • Serology/Genotyping
  • Special Transfusion Situations

Recommended

  • Neutralizing Antibodies to SARS-CoV-2 Persist for at Least 5 Months

  • Rapid Transfusions after Combat Causalities Improves Chances of Survival

  • Induced Abortion Does Not Increase Rh Alloimmunization

Show Comments

Comments on this article are closed.

Get the latest news. Subscribe to our mailing list. Sign Up

Primary Sidebar

Latest News

  • Directed Blood Donations Should be Limited

  • Babesia Infection Reduces Red Cell Deformability

  • New Erythropoietin Gene Variants Linked to Hereditary Erythrocytosis

  • Multifaceted Threats to the Blood Supply from Climate Change

    Question of the Day

    Copyright © 2025 John Wiley & Sons, Inc. All Rights Reserved.
    Privacy Policy

    Association for the Advancement of Blood and Biotherapies Wiley